Affordable Access

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.

Authors
Type
Published Article
Journal
PharmacoEconomics
Publication Date
Volume
23
Issue
6
Pages
619–637
Identifiers
PMID: 15960557
Source
Medline

Abstract

This Markov model allows, for the first time, a means of estimating the long-term cost effectiveness and cost utility of interventions for COPD. Initial evidence suggests that for patients with poorly reversible COPD and a documented history of frequent COPD exacerbations, the addition of salmeterol (a long-acting beta(2)-agonist) to fluticasone propionate (an inhaled corticosteroid) is potentially cost effective from the Canadian healthcare payer's perspective. However, the precision of this estimate will be improved when additional data are available from clinical trials such as the ongoing TORCH (TOwards a Revolution in COPD Health) study.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments